Glyco-Polypeptides (Comosain) and Chimeric White Blood Cell Therapy in Late-Stage Refractory Solid Carcinoma of Lung, Prostatic and Bladder Cancers Review of 35 Cases
Journal of Oncology Research and Therapy · 2021
DOI: 10.29011/2574-710x.010115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Research and Therapy, 2021.
Abstract (Originalsprache)
We employed Glyco-polypeptides in human subjects to induce leucocyte immune production which including interleukins and Tumor Necrotizing Factors (TNF) result in necrosis, fibrinolysis, anti-metastatic effects in late-stage carcinoma of lung, prostate, and bladder, and achieved excellent anti-tumor effects.Then investigation were carried out in animal.The cancer cells cultures were performed in our laboratory.By injection of cancer cell fluid into peritoneal cavity of animal in 6 groups (white rabbits).Tumor growth in animals were obtained in 3 months, then polypeptides were injected into peritoneal cavity every 2 weeks at a dose of 15 mg for 6 months, then animals were sacrificed and examined shown no tumor growth in the peritoneum.We applied FDA phase 2 clinical trials with IND 116911.Tests were carried out in 2 groups, the low dose group on 10 mg/kg/ day, and high dose group on 50 mg/kg/day for a period of more than 6-8 months.A total number of 35 patients with 3 rd and 4 th stage of refractory solid tumors of lung, prostate, and bladder were enrolled from referring center, 24 patients were not eligible and excluded, whom at least previously failed on two regimens of chemotherapy and /or failed on radiation therapy, the rates of complete response and partial responses in high dose cohort were astonishing with rate of 74% and 20% respectively.Stable diseases and Progressive diseases in high dose cohort were astonishing with rate of 0% and 5.7%.The implications and results of the findings are discussed.P value ≤0.05.Our findings in this study were correspondence with Dr. Maurer, Dr. Eckert, Dr. Harrach and many other authors.Glyco-polypeptides in treating various type of cancers only high dose are effective.There were no hematological, hepato-renal toxicities. Key points: Question:What are the most effective treatments in late stage of gynecological cancers?Finding: Since our patients have failed chemotherapy and radiation therapy, we are looking for new method to treat those clinical situations.We used Comosain in cancer treatment through our experience and literature evidence, which showed Comosain with remarkable effectiveness against most tumors.Meaning: In our clinical trial, we entered 14 patients into low dose cohort and 21 patients into high dose group.We transferred low dose group into high dose cohort due to ineffectiveness after 6 weeks.Total number of 35 high dose group patients were discussed and analyzed.
Zitieren
APA
(2021). Glyco-Polypeptides (Comosain) and Chimeric White Blood Cell Therapy in Late-Stage Refractory Solid Carcinoma of Lung, Prostatic and Bladder Cancers Review of 35 Cases. Journal of Oncology Research and Therapy. https://doi.org/10.29011/2574-710x.010115
Vancouver
Glyco-Polypeptides (Comosain) and Chimeric White Blood Cell Therapy in Late-Stage Refractory Solid Carcinoma of Lung, Prostatic and Bladder Cancers Review of 35 Cases. Journal of Oncology Research and Therapy. 2021. doi:10.29011/2574-710x.010115
BibTeX
@article{euvimed2021,
title = {Glyco-Polypeptides (Comosain) and Chimeric White Blood Cell Therapy in Late-Stage Refractory Solid Carcinoma of Lung, Prostatic and Bladder Cancers Review of 35 Cases},
journal = {Journal of Oncology Research and Therapy},
year = {2021},
doi = {10.29011/2574-710x.010115}
}
EUVIMED